about
DNA-dependent protein kinase catalytic subunit (DNA-PKcs)-SIN1 association mediates ultraviolet B (UVB)-induced Akt Ser-473 phosphorylation and skin cell survivalThe mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trialsTargeting RTK Signaling Pathways in CancerMolecular and Cellular Mechanisms of Action of Tumour Suppressor GAS5 LncRNARibosome profiling: a Hi-Def monitor for protein synthesis at the genome-wide scaleInhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significanceThe critical role of Akt in cardiovascular functionmTOR signaling in tumorigenesisThe Complex Roles of Mechanistic Target of Rapamycin in Adipocytes and Beyond.A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantationPilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer.Identification of a novel MTOR activator and discovery of a competing endogenous RNA regulating autophagy in vascular endothelial cellsCombined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression.Oral epithelial stem cells - implications in normal development and cancer metastasis.Induction of autophagy-dependent cell death by the survivin suppressant YM155 in salivary adenoid cystic carcinomaTelomerase expression abrogates rapamycin-induced irreversible growth arrest of uterine fibroid smooth muscle cells.Receptor-recognized α₂-macroglobulin binds to cell surface-associated GRP78 and activates mTORC1 and mTORC2 signaling in prostate cancer cells.Identification of two novel inhibitors of mTOR signaling pathway based on high content screening.Azithromycin synergistically enhances anti-proliferative activity of vincristine in cervical and gastric cancer cells.Galectin-1 is overexpressed in CD133+ human lung adenocarcinoma cells and promotes their growth and invasiveness.LARP1 post-transcriptionally regulates mTOR and contributes to cancer progressionHuman phospholipase D activity transiently regulates pyrimidine biosynthesis in malignant gliomasHistone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR SignalingTranslation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.Conessine Interferes with Oxidative Stress-Induced C2C12 Myoblast Cell Death through Inhibition of Autophagic FluxmicroRNA-153 Targets mTORC2 Component Rictor to Inhibit Glioma CellsDual PI3K/mTOR inhibitor NVP-BEZ235 suppresses hypoxia-inducible factor (HIF)-1α expression by blocking protein translation and increases cell death under hypoxia.Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivoCC-223 blocks mTORC1/C2 activation and inhibits human hepatocellular carcinoma cells in vitro and in vivo.The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells.PAT4 levels control amino-acid sensitivity of rapamycin-resistant mTORC1 from the Golgi and affect clinical outcome in colorectal cancerRestoration of Corticosteroid Sensitivity in Chronic Obstructive Pulmonary Disease by Inhibition of Mammalian Target of Rapamycin.Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.Pharmacological lifespan extension of invertebratesmTOR disruption causes intestinal epithelial cell defects and intestinal atrophy postinjury in mice.Ubiquilin-mediated Small Molecule Inhibition of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling.N-Hydroxyphthalimide exhibits antitumor activity by suppressing mTOR signaling pathway in BT-20 and LoVo cells.DEPTOR suppresses the progression of esophageal squamous cell carcinoma and predicts poor prognosis.Downregulation of p70S6K Enhances Cell Sensitivity to Rapamycin in Esophageal Squamous Cell CarcinomaAKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines.
P2860
Q24316008-C142960D-7FDE-4852-82E5-BF1E84A94BE9Q26751155-203002E8-EF1A-4274-9013-BF1A52055A88Q26781278-80039677-5A43-44AD-82F9-97DD70E94665Q26801277-114AB489-0D24-46D8-A856-9289ED17B7F9Q26822785-606EEA32-1E3B-4B4B-8D88-8607C233CA77Q26991637-954A4D02-014D-4835-A2A3-8D736C447283Q28083829-BA692841-04A7-4940-971E-8FBAE31AC327Q28252695-6E5F456B-C322-400A-A628-7D4178FCB96CQ30235555-BDA50D5E-EAF8-400B-AF9F-6098A4F935BDQ33573529-7B951EEB-915E-4811-A9E7-9EF7610D4FA2Q33858387-AC4F3EC0-B0DE-4D14-9B38-DCA96ACE425AQ33878961-8BC4D0F2-02DC-431E-AC7E-9A83C5DC90FFQ34135475-B715B5B8-752D-47FC-8255-D22A95CB3678Q34147649-26438663-21FC-4772-B54A-4C5E92557B99Q34412375-7389D7CC-CF5B-4A9E-9BE5-2490D8E4D943Q34418102-883956F3-980E-4729-9E8D-ECA82EAFC4FDQ34525572-8BAD187B-A3C9-451F-84EF-1E5DE3707863Q34915708-8BB9D468-2A0E-4E01-B92C-AF33DFCCAFCAQ35038110-F9415E08-4E75-41A2-AB3A-CF16A4E06032Q35550185-B92E5E9B-28B8-4864-B6C9-DE14CE38FF97Q35602365-7DFE8720-8763-497D-AC9C-52C6C976CEFBQ35612199-55A06298-F259-4796-8392-71E4FD0ED6A8Q35749913-DF4CBB3C-AE53-4CAC-9F7E-812F4041E240Q35832407-E5349057-0E51-4571-A4F3-FEAB779F9361Q36039323-448A88F9-B7DC-4C79-B682-F108033E81F3Q36050424-2E859C63-0497-4D97-94BD-FEAFB5B915E9Q36289917-E462DEB1-E53D-4C45-BE69-0D310388A6E6Q36296641-4F2F162B-50AC-46C6-A4DD-AF9CB90E361EQ36320156-4412BC4F-1EE0-4256-B81A-278B9CA82031Q36380974-CCD7190F-A6DF-43EB-BE55-CC170EAF1761Q36442548-9BD14DBF-39E1-4006-9025-227E415188DAQ36516850-B904A911-5474-4809-BE7D-EA1C7F122585Q36544967-D18E7B8C-E021-4ACE-B213-5CA7344E07D8Q36553629-63E38954-578B-4827-A645-6D95B60FB60BQ36570898-1EDB7C99-926D-4016-A70E-C5716A75CD91Q36650365-6E6299DB-9163-46E4-8430-D008551B3351Q36651651-4A9671A1-408A-41DD-9FAC-0B5567D0DADCQ37046569-24A84C72-363B-44D6-BA55-775CC9A15774Q37195321-C49BDAB3-10D0-4455-B8FB-D7DE185D8D78Q37225342-F6F6AF05-9FE5-46AD-9FA8-879A71F3836F
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
mTOR inhibitors in cancer therapy.
@ast
mTOR inhibitors in cancer therapy.
@en
mTOR inhibitors in cancer therapy.
@nl
type
label
mTOR inhibitors in cancer therapy.
@ast
mTOR inhibitors in cancer therapy.
@en
mTOR inhibitors in cancer therapy.
@nl
prefLabel
mTOR inhibitors in cancer therapy.
@ast
mTOR inhibitors in cancer therapy.
@en
mTOR inhibitors in cancer therapy.
@nl
P2093
P1433
P1476
mTOR inhibitors in cancer therapy.
@en
P2093
B Mark Evers
Joseph D Valentino
Pat Gulhati
Yekaterina Y Zaytseva
P356
10.1016/J.CANLET.2012.01.005
P407
P577
2012-01-17T00:00:00Z